Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Tagamet HB

This article was originally published in The Tan Sheet

Executive Summary

Tagamet HB: SmithKline's new OTC H2 antagonist captured an 18.6% share of the U.S. stomach remedies market the week ending Sept. 2, its third week on the market, CEO Jan Leschly told the Bear Stearns Health Care Conference in New York City on Sept. 21. J&J/Merck's Pepcid AC, which was introduced in June, held an 18.3% share the same week, according to Leschly. The overall stomach remedies market has been growing at an average rate of over 20% since the Pepcid AC launch, and the growth has accelerated with the entrance of Tagamet HB. The market grew 49% the week ending Sept. 2 and 61% the following week, SmithKline said...

Topics

UsernamePublicRestriction

Register

PS084318

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel